Want to learn more about how companies are working together to accelerate development of a plasma-derived hyperimmune globulin therapy against COVID-19? Join Georgia Bio as we welcome expert speakers from CSL Behring and Takeda, founding members of the CoVIg-19 Plasma Alliance.
COVID-19 is an unprecedented challenge. The CoVIg-19 Plasma Alliance is an unprecedented partnership of the world’s leading plasma companies, spanning plasma collection, development, production, and distribution. Rather than pursue our individual research, we are putting public and patient health first by working together. The goals are to accelerate the development of a potential treatment, improve chances of success, and increase supply of the potential treatment.
The CoVIg-19 Plasma Alliance is developing a hyperimmune globulin (H-Ig) called CoVIg-19. This potential medicine requires plasma donated by people who have fully recovered from COVID-19, since their plasma contains antibodies against the virus. Learn more here: https://www.covig-19plasmaalliance.org/en-us#recruitment.
The group discussion will be moderated by Maria Thacker Goethe, President & CEO of Georgia Bio.